$UEEC
United Health Products, Inc. Stock $ueec

$ueec Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000147793224007039 Filed on November 12, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$326.0K
YoY Change		-0.81%
% of Gross Profit
Research & Development		$65.89K
YoY Change		-45.89%
% of Gross Profit
Depreciation & Amortization		$1.010K
YoY Change
% of Gross Profit
Operating Expenses		$391.9K
YoY Change		-13.0%
Operating Profit		-$391.9K
YoY Change		-13.0%
Interest Expense		$7.613K
YoY Change		-51.75%
% of Operating Profit
Other Income/Expense, Net		$88.24K
YoY Change		-350.11%
Pretax Income		-$303.7K
YoY Change		-38.03%
Income Tax
% Of Pretax Income
Net Earnings		-$303.7K
YoY Change		-37.48%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share		$0.00
COMMON SHARES
Basic Shares Outstanding	250.1M shares	248.4M shares
Diluted Shares Outstanding		248.6M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$43.78K
YoY Change		-37.46%
Cash & Equivalents		$43.78K
Short-Term Investments
Other Short-Term Assets		$19.91K
YoY Change		-33.63%
Inventory		$0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$63.69K
YoY Change		-53.87%
LONG-TERM ASSETS
Property, Plant & Equipment		$54.73K
YoY Change		-31.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$2.850K
YoY Change		-96.44%
Total Long-Term Assets		$86.94K
YoY Change		-56.0%
TOTAL ASSETS
Total Short-Term Assets		$63.69K
Total Long-Term Assets		$86.94K
Total Assets		$150.6K
YoY Change		-55.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$926.6K
YoY Change		-17.27%
Accrued Expenses		$451.3K
YoY Change		167.0%
Deferred Revenue
YoY Change
Short-Term Debt		$707.5K
YoY Change		1.07%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$2.235M
YoY Change		8.36%
LONG-TERM LIABILITIES
Long-Term Debt		$150.0K
YoY Change
Other Long-Term Liabilities		$26.48K
YoY Change		-55.87%
Total Long-Term Liabilities		$176.5K
YoY Change		194.13%
TOTAL LIABILITIES
Total Short-Term Liabilities		$2.235M
Total Long-Term Liabilities		$176.5K
Total Liabilities		$2.262M
YoY Change		6.77%
SHAREHOLDERS EQUITY
Retained Earnings		-$77.89M
YoY Change		2.18%
Common Stock		$249.6K
YoY Change		3.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$2.111M
YoY Change
Total Liabilities & Shareholders Equity		$150.6K
YoY Change		-55.12%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$303.7K
YoY Change		-37.48%
Depreciation, Depletion And Amortization		$1.010K
YoY Change
Cash From Operating Activities		-$319.8K
YoY Change		-46.7%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		344.8K
YoY Change		-37.31%
NET CHANGE
Cash From Operating Activities		-319.8K
Cash From Investing Activities		0.000
Cash From Financing Activities		344.8K
Net Change In Cash		25.02K
YoY Change		-150.04%
FREE CASH FLOW
Cash From Operating Activities		-$319.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	150629	usd
CY2024Q3	ueec	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.00
CY2023Q3	ueec	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.00
	ueec	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.00
	ueec	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.01
	us-gaap	Profit Loss ProfitLoss	-1187621	usd
	us-gaap	Profit Loss ProfitLoss	-2151349	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19908	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	22804	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	63691	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	33598	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	151822	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	29362	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32400	usd
CY2024Q3	us-gaap	Assets Assets	150629	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	56115	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	54726	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	76520	usd
CY2024Q3	us-gaap	Security Deposit SecurityDeposit	2850	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	2850	usd
CY2023Q4	us-gaap	Assets Assets	284643	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	926603	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	987567	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1222174	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1979882	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	7613	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	15779	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95420	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	29640	usd
CY2023Q3	ueec	Interest Expense Related Parties InterestExpenseRelatedParties	19502	usd
	ueec	Interest Expense Related Parties InterestExpenseRelatedParties	57693	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	115085	usd
	us-gaap	Profit Loss ProfitLoss	-2151349	usd
CY2023Q1	ueec	Common Stock Issued For Litigation Settlement Amount CommonStockIssuedForLitigationSettlementAmount	462500	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001096938
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	249633222	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	244783222	shares
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q4	ueec	Debt Instruments Maturity Date DebtInstrumentsMaturityDate	2024-12-31
CY2022	ueec	Maturity Date Of Convertible Note MaturityDateOfConvertibleNote	December 31, 2023
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-27781
	dei	Entity Registrant Name EntityRegistrantName	UNITED HEALTH PRODUCTS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1517723
	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Fellowship Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite #D-406
	dei	Entity Address City Or Town EntityAddressCityOrTown	Mt. Laurel
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08054
	dei	City Area Code CityAreaCode	475
	dei	Local Phone Number LocalPhoneNumber	755-1005
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	250083222	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43783	usd
CY2024Q3	us-gaap	Deferred Costs DeferredCosts	0	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	21051	usd
CY2024Q3	ueec	Accrued Liabilities Related Parties AccruedLiabilitiesRelatedParties	421668	usd
CY2023Q4	ueec	Accrued Liabilities Related Parties AccruedLiabilitiesRelatedParties	226475	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28838	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	150000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	0	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	207500	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	207500	usd
CY2024Q3	ueec	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	500000	usd
CY2023Q4	ueec	Convertible Notes Payable Related Party ConvertibleNotesPayableRelatedParty	500000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2235411	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1950380	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26475	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48489	usd
CY2024Q3	us-gaap	Liabilities Liabilities	2261886	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1998869	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	249633222	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	244783222	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	249633	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	244783	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	75525941	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	74740201	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-77886831	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76699210	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-2111257	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1714226	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	284643	usd
CY2024Q3	us-gaap	Revenues Revenues	0	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	0	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	326018	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	328690	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	975017	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1534332	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65885	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	121761	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247157	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	445550	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	391903	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	450451	usd
	us-gaap	Operating Expenses OperatingExpenses	1222174	usd
	us-gaap	Operating Expenses OperatingExpenses	1979882	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-391903	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-450451	usd
	us-gaap	Interest Expense InterestExpense	22839	usd
	us-gaap	Interest Expense InterestExpense	32435	usd
CY2024Q3	ueec	Interest Expense Related Parties InterestExpenseRelatedParties	19231	usd
	ueec	Interest Expense Related Parties InterestExpenseRelatedParties	58500	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	115085	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-80532	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	88241	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-35281	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34553	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-171467	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-303662	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-485732	usd
	us-gaap	Profit Loss ProfitLoss	-1187621	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	248614744	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	241485939	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	247365704	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	237713870	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2064927	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	575855	usd
CY2023Q1	ueec	Common Stock Issued To Settle Accrued Liabilities Related Party Amount CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyAmount	168938	usd
CY2023Q1	ueec	Common Stock Issued To Settle Accrued Liabilities Amount CommonStockIssuedToSettleAccruedLiabilitiesAmount	79500	usd
CY2023Q1	ueec	Common Stock Issued For A Stock Subscription Receivable Amount CommonStockIssuedForAStockSubscriptionReceivableAmount	0	usd
CY2023Q1	ueec	Amortization Of Deferred Offering Costs AmortizationOfDeferredOfferingCosts	-55371	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1142706	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1976211	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	575725	usd
CY2023Q2	ueec	Common Stock Issued To Settle Accrued Liabilities Related Party Amount CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyAmount	102093	usd
CY2023Q2	ueec	Common Stock Issued To Settle Accrued Liabilities Amount CommonStockIssuedToSettleAccruedLiabilitiesAmount	74251	usd
CY2023Q2	ueec	Common Stock Issued For A Stock Subscription Receivable Amount CommonStockIssuedForAStockSubscriptionReceivableAmount	0	usd
CY2023Q2	ueec	Amortization Of Deferred Offering Costs AmortizationOfDeferredOfferingCosts	-55387	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-522911	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1802440	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	559213	usd
CY2023Q3	ueec	Amortization Of Deferred Offering Costs AmortizationOfDeferredOfferingCosts	-53769	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-485732	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1782728	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1714226	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	391225	usd
CY2024Q1	ueec	Amortization Of Deferred Offering Costs AmortizationOfDeferredOfferingCosts	-21051	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-451938	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1795990	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	225590	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-432021	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-2002421	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	194826	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-303662	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-2111257	usd
	us-gaap	Inventory Write Down InventoryWriteDown	33598	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	26502	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3038	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3038	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	582	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	346	usd
	ueec	Stock Issued For Litigation Settlement StockIssuedForLitigationSettlement	0	usd
	ueec	Stock Issued For Litigation Settlement StockIssuedForLitigationSettlement	462500	usd
	ueec	Gains Losses On Settlement Of Debt GainsLossesOnSettlementOfDebt	115085	usd
	ueec	Gains Losses On Settlement Of Debt GainsLossesOnSettlementOfDebt	-80532	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1132	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2896	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7504	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	54121	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-14040	usd
	ueec	Increase Decrease In Due To Related Party IncreaseDecreaseInDueToRelatedParty	195193	usd
	ueec	Increase Decrease In Due To Related Party IncreaseDecreaseInDueToRelatedParty	224698	usd
	ueec	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	0	usd
	ueec	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	-250000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1013278	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1624145	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	2850	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2850	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	usd
	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	4000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	19136	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	10200	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	12000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	821841	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1722793	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	150000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	961641	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1687657	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-51637	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	60662	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95420	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13377	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43783	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74039	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	15	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	ueec	Amortization Of Deferred Offering Cost AmortizationOfDeferredOfferingCost	21051	usd
	ueec	Amortization Of Deferred Offering Cost AmortizationOfDeferredOfferingCost	164527	usd
	ueec	Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability	0	usd
	ueec	Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiability	92425	usd
	ueec	Common Stock Issued To Settle Accrued Liabilities Related Party Non Cash CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyNonCash	0	usd
	ueec	Common Stock Issued To Settle Accrued Liabilities Related Party Non Cash CommonStockIssuedToSettleAccruedLiabilitiesRelatedPartyNonCash	218250	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	usd
	ueec	Common Stock Issued To Settle Accrued Liabilities Non Cash CommonStockIssuedToSettleAccruedLiabilitiesNonCash	0	usd
	ueec	Common Stock Issued To Settle Accrued Liabilities Non Cash CommonStockIssuedToSettleAccruedLiabilitiesNonCash	126000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The preparation of financial statements in conformity with generally accepted accounting principles requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reported period. Changes in the economic environment, financial markets, as well as in the healthcare industry, and any other parameters used in determining these estimates, could cause actual results to differ.</p>
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	0	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	33598	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	33598	usd
	ueec	Impaired And Written Off ImpairedAndWrittenOff	33598	usd
	ueec	Impaired And Written Off ImpairedAndWrittenOff	0	usd
	ueec	Description Of Patent DescriptionOfPatent	straight-line basis over the estimated useful life of 10 years
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11138	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8100	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3038	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3038	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1012	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4050	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4050	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4050	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4050	usd
CY2024Q3	ueec	Finite Lived Intangible Assets Amortization Expense Year Four Thareafter FiniteLivedIntangibleAssetsAmortizationExpenseYearFourThareafter	12150	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	29362	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	84616	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	84320	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	247157	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	445550	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">Certain accounts from prior periods have been reclassified to conform to the current period presentation. </p>
CY2022	ueec	Maturity Of Convertible Notes Payable MaturityOfConvertibleNotesPayable	December 31, 2023
	ueec	Debt Discount DebtDiscount	28000	usd
CY2024Q3	us-gaap	Accounts Payable Interest Bearing Current AccountsPayableInterestBearingCurrent	123822	usd
CY2023Q4	us-gaap	Accounts Payable Interest Bearing Current AccountsPayableInterestBearingCurrent	77287	usd
CY2022	ueec	Convertible Note Interest Rate ConvertibleNoteInterestRate	0.10	pure
CY2022	ueec	Original Issue Discount Rate OriginalIssueDiscountRate	0.07	pure
CY2022Q4	us-gaap	Share Price SharePrice	0.35
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	272250	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	134750	usd
CY2022	ueec	Issuance Of Convertible Note IssuanceOfConvertibleNote	100000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	107500	usd
CY2022	ueec	Proceeds From Convertible Note Debt ProceedsFromConvertibleNoteDebt	192975	usd
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.10	pure
CY2022	ueec	Original Issue Discount Rate OriginalIssueDiscountRate	0.07	pure
CY2022	ueec	Convertible Note Common Stock ConvertibleNoteCommonStock	0.35
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	14525	usd
CY2024Q3	ueec	Debt Unamortized Discount DebtUnamortizedDiscount	0	usd
CY2023Q4	ueec	Debt Unamortized Discount DebtUnamortizedDiscount	0	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	7613	usd
CY2024Q3	ueec	Investment Income Amortization Discount InvestmentIncomeAmortizationDiscount	0	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	8135	usd
CY2023Q3	ueec	Investment Income Amortization Discount InvestmentIncomeAmortizationDiscount	2811	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	22839	usd
CY2024Q3	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	usd
	ueec	Investment Income Amortization Discount InvestmentIncomeAmortizationDiscount	24541	usd
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	8569	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	49588	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	26749	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	150000	usd
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	1	pure
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	150000	usd
	ueec	Common Stock Issued For Litigation Settlement CommonStockIssuedForLitigationSettlement	1850000	shares
	ueec	Stock Issued For Litigation Settlement StockIssuedForLitigationSettlement	462500	usd
	ueec	Common Stock Purchase Agreement Description CommonStockPurchaseAgreementDescription	On June 20, 2024, the Company and White Lion amended the CSPA (the “Second Amendment”) to provide that the purchase price to be paid by White Lion for shares of the Company’s common stock pursuant to the CSPA equals the lower of: (i) 93% of the volume-weighted average price of the Company’s common stock during a period of five consecutive trading days following the Company’s exercise of its right to sell shares (or 95% of that volume-weighted average price if the Company’s common stock is trading on a national exchange), or (ii) the closing price of the common stock on the day the Company exercises its right to sell shares, subject to a floor price of $0.25 per share. The Second Amendment further provides that if the Company issues a share price purchase notice at a time that the Company’s common stock is trading below the floor price and White Lion waives the floor price condition, the purchase price to be paid by White Lion for such shares shall equal 90% multiplied by the
CY2024Q2	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	25313630	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	47665000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.54
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	47665000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.54
CY2024Q3	ueec	Cash Payment CashPayment	55532	usd
	ueec	Disgorgement Obligation DisgorgementObligation	171000	usd
	us-gaap	Litigation Settlement Gain LitigationSettlementGain	115085	usd
	us-gaap	Other Income OtherIncome	115085	usd
	ueec	Leases Description Of Security Deposite And Monthly Payments LeasesDescriptionOfSecurityDepositeAndMonthlyPayments	In May 2023, the Company entered into 36-month operating lease, which provides for approximately 1,800 square feet of office space, that commenced on June 1, 2023 and ends on May 31, 2026
	us-gaap	Increase Decrease In Time Deposits IncreaseDecreaseInTimeDeposits	2850	usd
	ueec	Lease Expiration Description LeaseExpirationDescription	at least ninety (90) days prior to the expiration date. The lease may be renewed for a term of one (1) year
	ueec	Initial Recognition Of Operating Lease Right Of Use Asset And Operating Lease Liability Non Cash InitialRecognitionOfOperatingLeaseRightOfUseAssetAndOperatingLeaseLiabilityNonCash	92425	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	26232	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	11746	usd
	ueec	Cash Paid For Lease Liabilities CashPaidForLeaseLiabilities	25650	usd
	ueec	Cash Paid For Lease Liabilities CashPaidForLeaseLiabilities	11400	usd
	ueec	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	P1Y8M1D
	ueec	Weighted Average Remaining Lease Term Years WeightedAverageRemainingLeaseTermYears	P2Y8M1D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2024Q3	ueec	Remaining Operating Lease Right Of Use Asset RemainingOperatingLeaseRightOfUseAsset	54726	usd
CY2023Q4	ueec	Remaining Operating Lease Right Of Use Asset RemainingOperatingLeaseRightOfUseAsset	76520	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	29640	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28838	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	26475	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	48489	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	56115	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	77327	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	8891	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	36394	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15410	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	60695	usd
CY2024Q3	us-gaap	Receivable With Imputed Interest Discount ReceivableWithImputedInterestDiscount	4580	usd

Files In Submission

Name	View Source	Status
0001477932-24-007039-index-headers.html	Edgar Link	pending
0001477932-24-007039-index.html	Edgar Link	pending
0001477932-24-007039.txt	Edgar Link	pending
0001477932-24-007039-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ueec-20240930.xsd	Edgar Link	pending
ueec_10q.htm	Edgar Link	pending
ueec_ex311.htm	Edgar Link	pending
ueec_ex312.htm	Edgar Link	pending
ueec-20240930_cal.xml	Edgar Link	unprocessable
ueec-20240930_def.xml	Edgar Link	unprocessable
ueec-20240930_pre.xml	Edgar Link	unprocessable
ueec-20240930_lab.xml	Edgar Link	unprocessable
ueec_10q_htm.xml	Edgar Link	completed
ueec_ex321.htm	Edgar Link	pending
ueec_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UEEC
United Health Products, Inc. Stock $ueec

2024 Q4 Form 10-Q Financial Statement

#000147793224007039 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UEEC United Health Products, Inc. Stock $ueec

2024 Q4 Form 10-Q Financial Statement

#000147793224007039 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UEEC
United Health Products, Inc. Stock $ueec